Compounds > 5-vinyluracil
Page last updated: 2024-11-07

5-vinyluracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-vinyluracil: RN given refers to unlabeled parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID99305
CHEMBL ID170188
SCHEMBL ID170251
MeSH IDM0079480

Synonyms (28)

Synonym
37107-81-6
nsc208961
nsc-208961
5-vinyluracil, 95%
bdbm50124204
5-vinyl-1h-pyrimidine-2,4-dione
5-ethenyl-1h-pyrimidine-2,4-dione
CHEMBL170188 ,
AKOS006223963
5-vinyluracil
5-ethenyl-2,4(1h,3h)-pyrimidinedione
fza8n5lef2 ,
unii-fza8n5lef2
nsc 208961
FT-0639360
SCHEMBL170251
ZRYZBEQILKESAW-UHFFFAOYSA-N
W-202533
mfcd00913267
DTXSID30190605
5-vinylpyrimidine-2,4(1h,3h)-dione
BBL102005
STL555804
5-ethenylpyrimidine-2,4(1h,3h)-dione
2,4(1h,3h)-pyrimidinedione, 5-ethenyl-
E78187
MS-20352
SB55659
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.08900.00040.908610.0000AID56039
Dihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)IC50 (µMol)0.08900.01400.13080.2200AID56039
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
purine nucleobase catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
pyrimidine nucleobase catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
thymine catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
uracil catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
thymidine catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
CMP catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
dCMP catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
beta-alanine biosynthetic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
UMP catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
dUMP catabolic processDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
dihydropyrimidine dehydrogenase (NADP+) activityDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
protein homodimerization activityDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
metal ion bindingDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
flavin adenine dinucleotide bindingDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
NADP bindingDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
4 iron, 4 sulfur cluster bindingDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
uracil bindingDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cytoplasmDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
cytosolDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
cytosolDihydropyrimidine dehydrogenase [NADP(+)]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID231335Ratio of tumor and plasma 5-FU concentration in HT-3 (human cervical cancer) xenograft mice on co-administration with Capecitabine2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
AID127783Tumour concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
AID56039Inhibitory activity against dihydropyrimidine dehydrogenase (DPD)2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
AID9768Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (60.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thymine
[no description available]		6.9510pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		3.0750pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.0110nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
deoxycytidine
[no description available]		2.0110pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
doxifluridine
doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.		2.0110organofluorine compound;
pyrimidine 5'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
prodrug
eniluracil
eniluracil: structure in first source; inactivates dihydropyrimidine dehydrogenase		2.0110pyrimidone
capecitabine
Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.		2.0110carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug
5-iodouracil
5-iodouracil: RN given refers to parent cpd. 5-iodouracil : An organoiodine compound consisting of uracil having an iodo substituent at the 5-position.		2.0110organoiodine compoundantimetabolite
5-cyanouracil
[no description available]		2.0110
5'-deoxy-5-fluorocytidine
5'-deoxy-5-fluorocytidine: structure in first source		2.0110N-glycosyl compound
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinoma, Non-Small Cell Lung
[description not available]		02.0110
Cancer of Cervix
[description not available]		02.0110
Cancer of Lung
[description not available]		02.0110
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.0110
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		02.0110
Lung Neoplasms
Tumors or cancer of the LUNG.		02.0110